Jasper Therapeutics Inc Stock Price, News & Analysis

Jasper Therapeutics (NASDAQ: JSPR) has received orphan drug designation from the European Medicines Agency for briquilimab, a monoclonal antibody targeting CD117, aimed at conditioning treatments before hematopoietic cell transplantation (HCT). This follows prior orphan drug status granted by the FDA in both HCT and for severe combined immunodeficiency (SCID). CEO Ronald Martell emphasized the importance of briquilimab in reducing toxicities associated with traditional conditioning. Clinical trials show promising results in SCID and acute myeloid leukemia patients, with no significant adverse events reported.

Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced positive results from a Phase 1/2 clinical trial involving briquilimab, aimed at treating sickle cell disease (SCD). All three participants achieved neutrophil engraftment within 12-16 days, with the first participant showing a significant increase in total hemoglobin from 8-9 g/dL to 13.3 g/dL at five months. The trial seeks to enhance donor cell chimerism while minimizing toxicity from conditioning regimens. The study is currently enrolling patients at the NHLBI.

Jasper Therapeutics, Inc. (JSPR) reported strong clinical data for JSP191 at the IEWP Annual Meeting, achieving 100% donor chimerism in two Fanconi Anemia patients. The FDA granted Fast Track designation for JSP191 in treating Severe Combined Immunodeficiency (SCID), highlighting a significant medical need. Upcoming studies include JSP191 for lower-risk myelodysplastic syndromes (MDS) and a registrational study in acute myeloid leukemia (AML) set for early 2023. Financially, the company reported a net loss of $11.9 million for Q3 2022, an increase from $3.4 million the previous year.

Jasper Therapeutics (NASDAQ: JSPR) reported promising results from a Phase 1/2 trial of JSP191 for treating Fanconi Anemia. The trial, held in Paris, showed that the first two patients achieved 100% donor chimerism with no adverse effects. Neutrophil and platelet engraftment were also observed within 11 and 14 days, respectively. JSP191 appears to offer a safer alternative to conventional therapies that typically involve toxic agents. Jasper plans further investigations of JSP191 across multiple indications, enhancing its pipeline for future developments.

Jasper Therapeutics (NASDAQ: JSPR) announced its participation in two key conferences in September 2022. The Cantor Fitzgerald Oncology Conference in New York City will feature CEO Ronald Martell on a panel discussing cell therapy challenges on September 28 at 9 AM ET. Additionally, Wendy Pang, SVP of Research, will present at the William Blair Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on September 29 at 5 PM ET. For more details and registration, visit their Investor Events webpage.

Jasper Therapeutics (Nasdaq: JSPR) announced that its anti-CD117 monoclonal antibody, JSP191, has received Fast Track designation from the FDA for patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant. JSP191 is currently being evaluated in four ongoing clinical studies related to Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and other conditions. The company is also on track to initiate a new study on JSP191 for second-line therapy in lower-risk MDS patients later this year.

Jasper Therapeutics (Nasdaq: JSPR) announced key developments in its clinical programs for the second quarter of 2022. The company dosed its first patient in a trial for JSP191 as a conditioning agent for Fanconi Anemia and is on track to initiate registrational studies in acute myeloid leukemia (AML) in early 2023. Financial results showed a net loss of $10.4 million, up from $8.4 million year-over-year, with cash reserves at $60.8 million, expected to last into early 2023. The firm is advancing multiple trials, highlighting the potential of JSP191 in treating hematopoietic stem cell diseases.

Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022. Ronald Martell, Jeet Mahal, and Wendy Pang will engage in a fireside chat at 4 PM ET, with a live webcast available on their website. The company focuses on developing innovative stem cell therapies, including JSP191, a monoclonal antibody aimed at improving hematopoietic cell transplants. Jasper plans to begin clinical studies for JSP191 in 2023, potentially transforming treatment for serious conditions like cancer.

Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the William Blair 42nd Annual Growth Stock Conference in Chicago from June 6-9, 2022. CEO Ronald Martell will present on June 9 at 8:00 AM CT, followed by a breakout session at 8:40 AM CT. A live webcast of the presentation will be accessible on the company's investor webpage. Jasper Therapeutics is focused on stem cell therapies, advancing programs such as JSP191, aimed at safer hematopoietic cell transplants. For more information, visit jaspertherapeutics.com.